EUVIMEDEUVIMED entdecken
Crossref

Engineered P. distasonis ‐Derived Membrane Vesicles Ameliorate Gut‐Liver Axis Disorders by Remodeling Intestinal Immunity and Bile Acid Homeostasis

Beibei Wu, Gelin Xiang iD, Zhilong Jia, Jun Zhao, Yutong Shu, Cuitong Wang, Xiao Li, Wenjing Wang iD, Fan Yang, Qinhui Liu, Li Mo iD, Yining Xu iD und 2 weitere

Small · 2026-11 · 22 (61)

DOI: 10.1002/smll.75446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Small, online erschienen am 28.08.2026. Verfasst von Beibei Wu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, West China School of Pharmacy, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Homeostasis, Bile Acids and Salts, Liver, Intestines. Die Arbeit nennt 67 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Innovation Group Project from Science & Technology Department of Sichuan Province, State Key Laboratory of Southwestern Chinese Medicine Resources.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The gut‐liver axis is a central conduit through which intestinal immunity and metabolism regulate liver health. Although gut probiotics such as Parabacteroides distasonis ( P. distasonis ) and their postbiotics show promise for treating related disorders, safety and stability concerns and inconsistent efficacy limit their further application. Here, outer membrane vesicles (OMVs) derived from P. distasonis are engineered (termed POTA) for enhanced oral delivery. Specifically, biomineralization with tannic acid and encapsulation within calcium alginate microbeads boost their anti‐inflammatory properties and enable targeted intestinal release. In mouse models of inflammatory bowel disease, POTA restores intestinal barrier integrity and suppresses inflammation by driving macrophage polarization from an M1 to M2 phenotype via fine‐tuned STING signaling. Furthermore, POTA reprograms intestinal immune homeostasis, particularly by rebalancing regulatory T (Treg) and T helper 17 (Th17) cell populations. These changes are supported by a restored microbiota and elevated levels of immunomodulatory bile acids, including isoallolithocholic acid (isoalloLCA). Notably, this localized gut intervention elicits systemic benefits, alleviating hepatic steatosis, inflammation, and insulin resistance in metabolic liver disease. Collectively, engineered bacterial OMVs represent a safe and effective oral platform for ameliorating gut‐liver axis disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HomeostasisBile Acids and SaltsLiverIntestinesAnimalsMiceMice, Inbred C57BLIntestinal Barrier FunctionInflammatory Bowel Diseases

Stichwörter der Autor:innen

bile acidsgut microbiomeinflammatory bowel diseaseintestinal immunitymetabolic dysfunction‐associated steatohepatitisouter membrane vesicles

Substanzen

Bile Acids and Salts

Autor:innen und Institutionen

  • Department of Pharmacy, West China School of Pharmacy, Sichuan University, Chengdu, China.
  • Department of Pharmacy, Institute of Metabolic Diseases and Pharmacotherapy, West China Hospital, Sichuan University, Chengdu, China.
  • Center of Gerontology and Geriatrics, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China.
  • State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, China.

ORCID-Profile: Gelin Xiang, Wenjing Wang, Li Mo, Yining Xu, Jinhan He

Förderung

  • National Natural Science Foundation of China
  • Innovation Group Project from Science & Technology Department of Sichuan Province
  • State Key Laboratory of Southwestern Chinese Medicine Resources
  • State Key Laboratory of Advanced Drug Delivery and Release Systems
  • National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University
  • Sichuan Province Science and Technology Support Program

Zitieren

APA

Wu, B., Xiang, G., Jia, Z., Zhao, J., Shu, Y., Wang, C., Li, X., Wang, W., Yang, F., Liu, Q., Mo, L., Xu, Y., Chen, W., & He, J. (2026). Engineered P. distasonis ‐Derived Membrane Vesicles Ameliorate Gut‐Liver Axis Disorders by Remodeling Intestinal Immunity and Bile Acid Homeostasis. Small, 22(61). https://doi.org/10.1002/smll.75446

Vancouver

Wu B, Xiang G, Jia Z, Zhao J, Shu Y, Wang C, et al. Engineered P. distasonis ‐Derived Membrane Vesicles Ameliorate Gut‐Liver Axis Disorders by Remodeling Intestinal Immunity and Bile Acid Homeostasis. Small. 2026;22(61). doi:10.1002/smll.75446

BibTeX
@article{Wu2026,
  author = {Wu, Beibei and Xiang, Gelin and Jia, Zhilong and Zhao, Jun and Shu, Yutong and Wang, Cuitong and Li, Xiao and Wang, Wenjing and Yang, Fan and Liu, Qinhui and Mo, Li and Xu, Yining and Chen, Wenfei and He, Jinhan},
  title = {Engineered P. distasonis ‐Derived Membrane Vesicles Ameliorate Gut‐Liver Axis Disorders by Remodeling Intestinal Immunity and Bile Acid Homeostasis},
  journal = {Small},
  year = {2026},
  volume = {22},
  number = {61},
  doi = {10.1002/smll.75446}
}
Kostenlos starten →